Achiko AG: Achiko Announces Provisional Patent Filing for Novel Low-Cost Saliva Covid-19 Test Kit

• A provisional patent for the novel DNA
  aptamer and saliva Covid-19 test kit has been lodged
• Codenamed “Gumnuts”, the test is
  extremely low cost, convenient and easy to use, significantly cheaper than
  current RNA and antigen-based test kits
• A world-class international team of scientist
  has been assembled for development and commercialisation
• Clinical trials will commence shortly, with
  a view to commercial availability before the end of 2020.

ZURICH, SWITZERLAND – EQS Newswire – 19 August 2020 – Achiko AG (SIX:ACHI, ISIN CH0522213468) is
pleased to announce progress with a non-intrusive and affordable novel Covid-19
test kit, codenamed “Gumnuts”. With the assistance from Australian
intellectual property firm FB Rice (Melbourne), developer Regenacellx.sl
(“RCX”) has filed a provisional patent over the technology. Achiko
holds the exclusive commercialisation rights in exchange for a royalty and
technical advice.

The Company has assembled a world-class internationally recognised team for
the development and commercialisation of Gumnuts. The team is led by Dr Michael
J. Edel (Chief Scientist) and Dr Thomas Pouplin, joined by Dr Jittaporn
Wattanaseree and Dr Joalin Lim. Additionally, a larger science and
commercialisation organisation that spans across Spain, Switzerland, Thailand,
Singapore and Indonesia supports the team.

The planned Gumnuts kit is assembled around DNA aptamers and gold
nanoparticles, combined with a saliva sample, and is proceeding to clinical
trials shortly.

“After a significant number of years, projects and papers on
nanoparticle bio-conjugation, we are now engaging studies on
nanoparticle-aptamer bioconjugates for detection and actuation. What appeals in
aptamers to us is their chemical robustness. This eases their industrial
production while facilitating their use, as they offer longer shelf-life,
tolerance to environmental changes and more stable performance in different
media”, said Dr Victor Pentes, ICREA Research Professor, Instituci�
Catalana de Recerca i Estudis Avançats, VHIR and ICN2, Barcelona.

The first of many diagnostics planned to use the technology, Gumnuts is
designed to be affordable and convenient. It delivers results in minutes and
the testing experience is comparable to brushing one’s teeth. Sold alone or
combined with Achiko’s pandemic management platform Teman Sehat (“Health
Buddy”), the Company believes that the technology play a crucial role in
resolving the world’s problem with the pandemic.

Gumnuts has several differentiators and advantages over PCR, RT-PCR, LAMP,
antigen and antibody test kits, all of which are currently being used globally.
Current testing approaches may be constrained by reagents (supply chain, shelf
life, etc.) or the required equipment (PCR/RT-PCR machines, trained
technicians, etc.). They are confined in practical use (e.g. time to results,
invasiveness, etc.) and suffer from accuracy issues (e.g. antigen tests) or
high cost due to their structure. In contrast, DNA aptamers are known to be
comparatively stable and may have a shelf life of more than a year at room
temperature. The prospective materials required by Gumnuts may cost less than
USD 1.00, dropping to only be a few cents when mass-produced. This opens up a
realm of possibility for embedding testing in day-to-day applications beyond
the approaches known to date.

“The Covid-19 pandemic has had an enormous impact around the world. To
respond effectively, a precise and fast diagnosis is needed. The current
testing technologies around PCR, antigen, and antibody test have problems such
as the high cost of PCR tests and the time it takes to deliver results.
Antibody tests miss the infection cycle and there are design weaknesses and
reliability problems with antigen testing,” said Dr Abdullah Qayyum,
Epidemiologist, Riau Hospital Supervisory Agency, Indonesia. “Low cost and
effective testing are key elements in responding to the pandemic. Research in
alternative methods is needed now. We are excited to be involved in this
project doing research and testing.”

Clinical trials are set to begin shortly. If the trials prove successful,
large-scale production of the test kit will begin with a view to commercial
availability before the end of 2020. Currently, the Company is selecting
manufacturers as well as distribution partners. It is also continuing
development at a wider range of assay approaches for Covid-19.

“Our novel test kit is a comprehensive offering for government and
industry, seeking solutions to manage their economies, sporting events, travel,
education, etc. We’re excited about and encouraged by the progress with
vaccines. However, the Company believes that testing will be an issue for many
years to come,” says Steven Goh, CEO and Director of Achiko. “Along
with Teman Sehat, our suite of solutions may allow governments and businesses
to move to a broader proactive testing approach covering nearly the entire
population.”

Beyond the initial application of DNA aptamers to the Covid-19 pandemic and
an array of assay formats (electronic, lateral, etc.), the Company is looking
towards diagnostics for dengue, tuberculosis, cancer biomarkers and numerous
other pathogens and believes that in combination with Teman Sehat, the
technology may form the foundation of a diagnostics-as-a-service and telehealth
business.

The issuer is solely responsible for the content of this announcement.

 

Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Achiko AG and its business. Such statements involve
certain known and unknown risks, uncertainties and other factors, which could
cause the actual results, financial condition, performance or achievements of
Achiko AG to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Achiko AG
is providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.

About Achiko AG

Headquartered in Switzerland, with a global market focus, Achiko AG (ISIN
CH0522213468) is an entrepreneurial platform company, utilising the knowledge
and experience of its people and key technologies to enable transformation in
various industries.

Through innovations in technology and regulation along with the company’s
unique operating footprint from Europe to Asia, Achiko seeks to transform
markets and bring unique value to its customers, people, and shareholders.
Achiko’s core platform consists of user registration and payment services which
are accessible to application developers. A messaging service and other
community based social features are being launched in late 2020. Achiko
supports innovations in healthcare through its Teman Sehat (“Health Buddy”)
ecosystem, a novel testing technology being developed with Regenacellx.sl, as
well as consumer payments and finance and games and entertainment.

For any inquiries regarding Teman Sehat or Gumnuts, please contact info@achiko.com

Further information about Achiko AG can be found at https://www.achiko.com

Further information about the Teman Sehat ecosystem can be found at https://www.temansehat.co

Further information about Regenacellx.sl can be found at https://regenacellx.com

For further Information about the research and development team:

– Dr Michael J. Edel, chief scientist ( https://regenacellx.com )

– Dr Jittaporn Wattanaseree ( http://www.thaitect.org/committee/Jittaporn_EN.pdf
)

– Dr Thomas Pouplin ( https://www.tropmedres.ac/team/thomas-pouplin
)

– Dr Joalin Lim, ( https://www.agape-lifess.com/
)

– Prof. Dr Víctor F. Puntes, ( http://www.inorganicnanoparticles.net/about/victor-puntes/
)

– Dr Abdullah Qayyum ( https://www.linkedin.com/in/dr-abdullah-qayyum-091aa475
)